about
I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe[Influenza surveillance. New solutions to an old problem]."I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9.[Excess mortality in Spain during transmission of pandemic influenza in 2009].Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain.Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in SpainUsing surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010.Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study.[Premature mortality excess related to influenza in Spain during an interpandemic period].Epidemiology of the 2009 influenza pandemic in Spain. The Spanish Influenza Surveillance System.Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003-2011.Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data.Impact of flu on hospital admissions during 4 flu seasons in Spain, 2000-2004Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project.Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination.Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method.A surveillance network for meningococcal disease in Europe.Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza.Pilot study to harmonize the reported influenza intensity levels within the Spanish Influenza Sentinel Surveillance System (SISSS) using the Moving Epidemic Method (MEM).I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15.Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project.Excess mortality among the elderly in European countries, December 2014 to February 2015.Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016.Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014.Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13.Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study.Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo.[Excess mortality associated with influenza in Spain in winter 2012].A cytochemical stain for glutathione in rat hepatocytes cultured on plastic.[Conclusions of the workshop "Results and lessons learned during the pandemic flu (H1N1) 2009 from the research and the public health surveillance"].Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network--pilot case-control studies using different control groups, 2008-2009 season, Spain.Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season.2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children.Climatic Factors and Influenza Transmission, Spain, 2010-2015.Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.Influenza-related mortality in Spain, 1999-2005.
P50
Q28742719-057422C1-EB04-4399-AA00-CDB6427DFEC5Q30353391-409917CC-C52D-43E0-BC45-D63C411F7380Q30382891-C40A3B1C-2A6F-41F1-A07C-B277019E806FQ30398110-FDCD04B3-C6B9-4A17-8975-6B428A7C53BCQ30402857-013A265E-3DB0-48FA-A77B-BD62C72B6EA8Q30403059-282A3F53-06B4-46D7-AA85-ACBF64FF5223Q30410112-E303AA49-B939-478A-AADD-57038B94BB11Q30414952-9790F9CE-C76D-4516-9561-7A4D27776F8AQ30421430-3F7E0197-6ECA-4EB7-919A-CAC6C2E5245BQ30423089-805E87F6-0C1E-4C14-8B06-9E33F3F7ACABQ30833500-A6B595CE-9B96-454E-81F3-D69A1F534C2EQ30982712-82B5391E-C207-420C-81B1-272310241A70Q33293625-9C220E0B-10CF-48C7-A321-79D9CCC49430Q33553253-7F90B139-4D29-4642-82B0-EDCB1B35CFD9Q33876458-61B9E11D-E945-4C59-B299-73F0263E2327Q33931458-E6E6BAF2-6B69-4AF5-AE55-E558C5CB3F0AQ34993133-640368E9-4140-4F8E-AD08-1FA153F80829Q35994974-BFFECC74-1AAC-430F-A0AB-3223938DE7B5Q36683965-9F86952A-8875-4515-B532-0949820E9163Q38678530-4BC91CC4-AD1C-48B0-BAC1-6D59980F5E36Q39132734-E12117E7-CBF6-4E96-9248-16D610B325C6Q39813822-D890951A-2837-4CD1-B76F-F1FE2B37EBFBQ39884379-A84885CB-34EE-4330-921E-4F302634431BQ39961932-6BDF1B11-A50B-4D83-847A-B0669709B1FEQ40087098-2EB00729-7891-4946-AF27-6DBB6F8AB34AQ41381181-11F3026A-CBC0-40B3-832D-6C5C24F5EDC4Q41928075-59DF4EA1-0027-4770-B631-84F773262CE6Q42148972-EF9DD25F-D3F9-4729-8FFB-E93837B0F266Q42227573-1D520073-6891-46A4-BC44-AD605254C772Q42231717-095EBFE3-41A9-41B3-8895-31D4E0998D25Q42479399-74CAEDE0-AF69-4DA2-9E03-D8A1BF98FD30Q44146929-A529F06F-A392-4C0C-A8BF-EE4BE786CBF4Q44804331-B37480F7-50E1-41AE-A655-133B546A0A3EQ44914247-DA9890F0-701C-415D-95E2-79EFC34CEE6DQ45792636-222AE083-FDF8-44BA-A218-C499965D6609Q47135577-845E7663-FB32-4B82-8108-47F042E154B0Q47583920-6F09D38B-E469-4EE6-8E27-82C957F5B7F4Q47697679-713B09B7-4B82-4B99-A4EA-DD8327414092Q50765655-3D1EFF87-F871-4886-9CC0-0DD8DDA47683Q51177195-DB07AEDD-BCC8-4A70-A1EE-E54AAE8AB5AE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Amparo Larrauri
@ast
Amparo Larrauri
@en
Amparo Larrauri
@es
type
label
Amparo Larrauri
@ast
Amparo Larrauri
@en
Amparo Larrauri
@es
prefLabel
Amparo Larrauri
@ast
Amparo Larrauri
@en
Amparo Larrauri
@es
P1053
Q-9613-2017
P106
P21
P31
P3829
P496
0000-0002-1704-2245